{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:11:15Z","timestamp":1792735875784,"version":"4.5.0"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Purpose: Pleomorphic xanthoastrocytoma (PXA) is an uncommon astrocytoma that tends to occur in children and young adults and has a relatively favorable prognosis. The 2021 WHO classification of tumors of the central nervous system (CNS WHO), 5th edition, rates PXAs as grade 2 and grade 3. The histological grading was based on mitotic activity (\u22652.5 mitoses\/mm2). This study specifically evaluates the clinical, morphological, and, especially, the molecular characteristics of grade 2 and 3 PXAs. Methods: Between 2003 and 2021, we characterized 53 tumors with histologically defined grade 2 PXA (n = 36, 68%) and grade 3 PXA (n = 17, 32%). Results: Compared with grade 2 PXA, grade 3 PXA has a deeper location and no superiority in the temporal lobe and is more likely to be accompanied by peritumoral edema. In histomorphology, epithelioid cells and necrosis were more likely to occur in grade 3 PXA. Molecular analysis found that the TERT promoter mutation was more prevalent in grade 3 PXA than in grade 2 PXA (35% vs. 3%; p = 0.0005) and all mutation sites were C228T. The cases without BRAF V600E mutation or with necrosis in grade 3 PXA had a poor prognosis (p = 0.01). Conclusion: These data define PXA as a heterogeneous astrocytoma. Grade 2 and grade 3 PXAs have different clinical and histological characteristics as well as distinct molecular profiles. TERT promoter mutations may be a significant genetic event associated with anaplastic progression. Necrosis and BRAF V600E mutation play an important role in the prognosis of grade 3 PXA.<\/jats:p>","DOI":"10.3390\/curroncol30020183","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T02:57:22Z","timestamp":1676602642000},"page":"2405-2416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6075-4299","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"first","affiliation":[{"name":"Departments of Clinical Pathology, The Second Affiliated Hospital of Medical College of Zhejiang University, 88 Jiefang Road, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Ma","sequence":"additional","affiliation":[{"name":"Departments of Clinical Pathology, The Second Affiliated Hospital of Medical College of Zhejiang University, 88 Jiefang Road, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ping","family":"Xiang","sequence":"additional","affiliation":[{"name":"Departments of Clinical Pathology, The Second Affiliated Hospital of Medical College of Zhejiang University, 88 Jiefang Road, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Yuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Departments of Clinical Radiography, The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Long","family":"Tang","sequence":"additional","affiliation":[{"name":"Departments of Clinical Pathology, The Second Affiliated Hospital of Medical College of Zhejiang University, 88 Jiefang Road, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Yu","sequence":"additional","affiliation":[{"name":"Departments of Clinical Pathology, The Second Affiliated Hospital of Medical College of Zhejiang University, 88 Jiefang Road, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Hong","family":"Xu","sequence":"additional","affiliation":[{"name":"Departments of Clinical Pathology, The Second Affiliated Hospital of Medical College of Zhejiang University, 88 Jiefang Road, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"ref_1","unstructured":"Louis, D.N., Ohgaki, H., Wiestler, O.D., and Cavenee, W.K. (2021). Anaplastic Pleomorphic Xanthoastrocytoma, WHO Classification of Tumors of the Central Nervous System."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bpa.12295","article-title":"Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytoma\u2014Same entity or first cousins?","volume":"26","author":"Alexandrescu","year":"2016","journal-title":"Brain Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shaikh, N., Brahmbhatt, N., Kruser, T.J., Kam, K.L., Appin, C.L., Wadhwani, N., Chandler, J., Kumthekar, P., and Lukas, R.V. (2019). Pleomorphic xanthoastrocytoma: A brief review. CNS Oncol., 8.","DOI":"10.2217\/cns-2019-0009"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/neup.12459","article-title":"Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma","volume":"38","author":"Furuta","year":"2018","journal-title":"Neuropathology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bpa.12217","article-title":"Pleomorphic xanthoastrocytoma: Natural History and long-term follow-up","volume":"25","author":"Ida","year":"2015","journal-title":"Brain Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bpa.12111","article-title":"BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression","volume":"24","author":"Koelsche","year":"2014","journal-title":"Brain Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11060-012-0991-4","article-title":"Anaplastic PXA in adults: Case series with clinicopathologic and molecular features","volume":"111","author":"Schmidt","year":"2013","journal-title":"J. Neurooncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bpa.12495","article-title":"Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation","volume":"28","author":"Vaubel","year":"2018","journal-title":"Brain Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bpa.12874","article-title":"Biology and grading of Pleomorphic xanthoastrocytoma-what have we learned about it?","volume":"31","author":"Vaubel","year":"2021","journal-title":"Brain Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/sj.onc.1209851","article-title":"Frequent loss of chromosome 9, homozygous CDKN2A\/p 14 ARF\/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas","volume":"26","author":"Weber","year":"2007","journal-title":"Oncogene"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bpa.12639","article-title":"The genetic landscape of anaplastic pleomorphic xanthoastrocytoma","volume":"29","author":"Phillips","year":"2019","journal-title":"Brain Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lohkamp, L.-N., Schinz, M., Gehlhaar, C., Guse, K., Thomale, U.-W., Vajkoczy, P., Heppner, F.L., and Koch, A. (2016). MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156422"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.0.CO;2-Z","article-title":"Pleomorphic xanthoastrocytoma: What do we really know about it?","volume":"85","author":"Giannini","year":"1999","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.21037\/apm-20-640","article-title":"Overview of prognostic factors in adult gliomas","volume":"10","author":"Akanksha","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/brain\/awt345","article-title":"Epileptic seizures in diffuse low-grade gliomas in adults","volume":"137","author":"Pallud","year":"2014","journal-title":"Brain"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11060-012-0939-8","article-title":"Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: A SEER analysis","volume":"110","author":"Perkins","year":"2012","journal-title":"J. Neurooncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1225","DOI":"10.1016\/j.wneu.2018.09.050","article-title":"BRAF V600E, TERT, and IDH2 mutations in pleomorphic xanthoastrocytoma: Observations from a large case-series study","volume":"120","author":"Ma","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ebrahimi, A., Korshunov, A., Reifenberger, G., Capper, D., Felsberg, J., Trisolini, E., Pollo, B., Calatozzolo, C., Prinz, M., and Staszewski, O. (2022). Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathol. Commun., 10.","DOI":"10.1186\/s40478-021-01308-1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.ejso.2015.09.012","article-title":"BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma","volume":"41","author":"Tabouret","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/neup.12318","article-title":"Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma","volume":"37","author":"Matsumura","year":"2017","journal-title":"Neuropathology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Liu, R., Zhang, T., Zhu, G., and Xing, M. (2018). Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer. Nat. Commun., 9.","DOI":"10.1038\/s41467-018-03033-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.humpath.2018.08.038","article-title":"Molecular features of pleomorphic xanthoastrocytoma","volume":"86","author":"Zou","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/PAS.0000000000000363","article-title":"BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation","volume":"39","author":"Aisner","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00401-018-1905-0","article-title":"Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma","volume":"136","author":"Stichel","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/PAS.0b013e3181ce107b","article-title":"Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not Gaudin 6","volume":"34","author":"Alassiri","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Lachance","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Diplas, B.H., He, X., Brosnan-Cashman, J.A., Liu, H., Chen, L.H., Wang, Z., Moure, C.J., Killela, P.J., Loriaux, D.B., and Lipp, E.S. (2018). The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat. Commun., 9.","DOI":"10.1038\/s41467-018-04448-6"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.wneu.2018.12.095","article-title":"Role of a promoter mutation in TERT in Malignant Transformation of pleomorphic xanthoastrocytoma","volume":"126","author":"Hosono","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with the highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/2\/183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:38:27Z","timestamp":1760121507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/2\/183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["curroncol30020183"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30020183","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}